DDrare: Database of Drug Development for Rare Diseases

Searched query = "Myelomeningocele", "Myeloschisis", "Myelocele", "Myelocystocele", "Syringomyelocele"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Atosiban; Botulinum A toxin; Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique; Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique; Device: Minimally invasive fetoscopic repair of MMC; Device: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics); MMC; MONITOR; Placental Mesenchymal Stem Cells; Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix; Procedure: Fetal surgery for MMC repair; Procedure: endoscopic repair of myelomeningocele before 26 SA; SA; Terbutaline; Uterine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00175123 (ClinicalTrials.gov)	May 2005	9/9/2005	Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele	Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele	Myelomeningocele;Bladder, Neurogenic	Drug: Botulinum A toxin	University of Aarhus	Aarhus University Hospital	Active, not recruiting	2 Years	16 Years	Both	30	Phase 4	Denmark

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00175123
(ClinicalTrials.gov)

May 2005

9/9/2005

Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele

Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele

Myelomeningocele;Bladder, Neurogenic

Drug: Botulinum A toxin

University of Aarhus

Aarhus University Hospital

Active, not recruiting

2 Years

16 Years

Both

Phase 4

Denmark